Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18858528 | 0.80 | GABRA1 (0.38) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL15858739 | 0.78 | GABRA1 (0.36) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL13599964 | 0.78 | P2RX3 (0.41) | GABRA1GABRB2LMNANOS3NOS1 | |
| SCHEMBL18856278 | 0.78 | GABRA1 (0.36) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL25510587 | 0.76 | GABRA1 (0.35) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL12197960 | 0.76 | NOS3 (0.36) | LMNANOS3NOS1NOS2 | |
| SCHEMBL12413800 | 0.76 | GABRA1 (0.35) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL24331534 | 0.75 | GABRA1 (0.38) | GABRA1GABRB2PTGS1PTGS2LMNA | |
| SCHEMBL14423633 | 0.75 | TUBB4A (0.38) | GABRA1GABRB2CXCR1CXCR2 | |
| SCHEMBL14451743 | 0.75 | LMNA (0.38) | GABRA1GABRB2LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | GABRA1 1882/4885GABRB2 2786/4885PTGS1 438/4885 |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | GABRA1 292/4885GABRB2 235/4885PTGS1 596/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | GABRA1 3502/4885GABRB2 4068/4885PTGS1 518/4885 |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | HRH4, HRH3, HRH2 | GABRA1 1134/4885GABRB2 1671/4885PTGS1 1951/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | GABRA1 3502/4885GABRB2 4068/4885PTGS1 518/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | GABRA1 3502/4885GABRB2 4068/4885PTGS1 518/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | GABRA1 3502/4885GABRB2 4068/4885PTGS1 518/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | GABRA1 2922/4885GABRB2 2882/4885PTGS1 156/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | GABRA1 3463/4885GABRB2 3570/4885PTGS1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.